A Phase II Study of Combined Fulvestrant (Fulvestrant) and RAD001 (Everolimus) in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

Grants and Contracts Details

StatusFinished
Effective start/end date4/1/0812/31/15

Funding

  • Novartis (domestic): $358,355.00